Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188678 | 0.94 | FFAR4 (0.46) | FFAR4KDM4EPPARAPPARDALDH1A1 | |
| SCHEMBL4186160 | 0.90 | FFAR4 (0.47) | FFAR4KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4199991 | 0.90 | FFAR4 (0.48) | FFAR4FFAR1PPARAPPARDPPARG | |
| SCHEMBL4202648 | 0.89 | FFAR4 (0.45) | FFAR4KDM4EFFAR1PPARAPPARD | |
| SCHEMBL4198421 | 0.88 | KDM4E (0.43) | FFAR4KDM4EPPARAPPARDALDH1A1 | |
| SCHEMBL4197503 | 0.87 | FFAR4 (0.48) | FFAR4KDM4EPPARAPPARDALDH1A1 | |
| SCHEMBL4197864 | 0.87 | FFAR4 (0.47) | FFAR4KDM4EPPARAPPARDALDH1A1 | |
| SCHEMBL4197206 | 0.87 | HDAC1 (0.46) | FFAR4FFAR1PPARAPPARDPPARG | |
| SCHEMBL4198178 | 0.87 | FFAR4 (0.42) | FFAR4KDM4EPPARAPPARDALDH1A1 | |
| SCHEMBL4204186 | 0.84 | PPARG (0.42) | KDM4EPPARAPPARDSMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627867-B1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-7534909-B2 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1627867-A1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | METTL14, PAM, TAS2R41 | FFAR4 1889/4885KDM4E 270/4885FFAR1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.